Intestinal obstruction following antituberculosis therapy in a patient with pancreatic carcinoma and pulmonary tuberculosis: a case report

被引:0
作者
Hong, Wei [1 ]
Zhang, Lei [1 ]
Yu, Zunshun [1 ]
Wang, Yanjun [1 ]
Qi, Youkun [1 ]
机构
[1] Second Peoples Hosp Liaocheng, 306 Hlth St, Linqing, Shandong, Peoples R China
关键词
Intestinal obstruction; Antituberculosis drugs; Pancreatic carcinoma; Primary pulmonary tuberculosis; Case report; DISEASES SOCIETY;
D O I
10.1186/s13256-024-04849-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionIntestinal obstruction is a common complication in patients with advanced malignancies, often attributed to the disease itself or as a side effect of opioid analgesics used for pain management. However, the occurrence of intestinal obstruction following antituberculosis therapy is rare.Case presentationWe report a unique case of a 58-year-old Asian male diagnosed with stage IV pancreatic carcinoma and pulmonary tuberculosis. The patient was initiated on a regimen of ethambutol hydrochloride, pyrazinamide, rifampicin, and isoniazid tablets (II) for tuberculosis, alongside morphine for the management of severe cancer-related pain. Subsequently, he developed symptoms indicative of intestinal obstruction. Despite discontinuation of morphine, the patient's symptoms persisted until he autonomously ceased all medications, leading to a rapid improvement in his condition. This unexpected resolution highlighted the antituberculosis drugs as the probable cause of his intestinal obstruction.ConclusionsThis case underscores the importance of considering antituberculosis drugs as a potential cause of intestinal obstruction, especially in patients who do not respond to conventional management strategies for drug-induced gastrointestinal side effects. It also emphasizes the need for heightened vigilance and monitoring when prescribing these medications to patients with advanced malignancies, to promptly identify and address rare but significant side effects.
引用
收藏
页数:5
相关论文
共 15 条
[1]  
Akbarali HI, 2022, ADV CANCER RES, V155, P131, DOI 10.1016/bs.acr.2022.02.007
[2]   Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits [J].
Camilleri, Michael ;
Lembo, Anthony ;
Katzka, David A. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (09) :1338-1349
[3]   Isoniazid-induced myopathy [J].
Chaouch, N. ;
Mejid, M. ;
Zarrouk, M. ;
Racil, H. ;
Rouhou, S. Cheikh ;
El Euch, G. ;
Chabbou, A. .
REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 (06) :354-358
[4]   Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin [J].
Combrink, Monique ;
Loots, Du Toit ;
du Preez, Ilse .
TOXICOLOGY LETTERS, 2020, 322 :104-110
[5]   Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials [J].
Geng, Chun-Jing ;
Liang, Qian ;
Zhong, Jian-Hong ;
Zhu, Min ;
Meng, Fan-Ying ;
Wu, Ning ;
Liang, Rui ;
Yuan, Bin-Yi .
BMJ OPEN, 2015, 5 (06)
[6]   Opioid receptors in the gastrointestinal tract [J].
Holzer, Peter .
REGULATORY PEPTIDES, 2009, 155 (1-3) :11-17
[7]   Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug [J].
Hussain, Zahir ;
Zhu, Junjie ;
Ma, Xiaochao .
DRUG METABOLISM AND DISPOSITION, 2021, 49 (08) :679-682
[8]  
Kim Hae Koo, 2017, Korean J Gastroenterol, V69, P308, DOI 10.4166/kjg.2017.69.5.308
[9]  
Lee Chien-Wei, 2009, Int J Infect Dis, V13, pe185, DOI 10.1016/j.ijid.2008.09.016
[10]  
Lewinsohn DM, 2017, CLIN INFECT DIS, V64, P111, DOI [10.1093/cid/ciw778, 10.1093/cid/ciw694]